Bei Akademie registrieren
Sanofi S.A., FR0000120578

Sanofi stock: Analysts lift targets as outlook stays in focus

Published on 11/10/2026 at 11:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sanofi stock drew analyst support as Exane BNP Paribas turned bullish and UBS raised its target. The revisions add a valuation signal after the recent outlook upgrade.

Analysts Raise Sanofi Targets

  • Exane BNP Paribas upgraded Sanofi to Outperform and raised its target to 102 euros.
  • UBS kept a Hold rating but lifted its target to 88 euros.
  • The revisions add a valuation signal after Sanofi raised its 2026 outlook.
Sanofi S.A., FR0000120578, Illustration mit AI erstellt.
Sanofi S.A., FR0000120578, Illustration mit AI erstellt.

Sanofi stock is back in focus after fresh analyst changes added support to the French drugmaker's valuation story. Exane BNP Paribas upgraded the shares from Neutral to Outperform and raised its target from 79 euros to 102 euros, according to an analyst review published by Ideal Investor on November 9 and updated on November 10, 2026.

Broker Views Move Higher

UBS retained its Hold rating while lifting its target from 78 euros to 88 euros. The report put the median target at 90 euros and identified the latest revisions as part of a broader set of analyst changes across French equities.

The split between a more bullish rating from Exane BNP Paribas and a cautious Hold stance from UBS gives investors two different readings of Sanofi's near-term risk and reward. The higher targets point to improved valuation expectations, but they remain analyst estimates rather than company guidance.

Outlook Remains The Key Driver

The analyst revisions follow Sanofi's stronger third-quarter performance and higher 2026 outlook, which have kept Dupixent and the group's newer medicines at the center of the investment case. Investors are also weighing how Sanofi can replenish its pipeline and sustain growth beyond Dupixent's period of market exclusivity.

Sanofi stock traded at 85.52 euros on Lang & Schwarz at 11:33 CET on Tuesday, November 10, 2026.

Sanofi at a Glance

  • Company: Sanofi S.A.
  • ISIN: FR0000120578
  • Trading venue: Lang & Schwarz
  • Price: 85.52 euros at 11:33 CET on November 10, 2026
  • Analyst target: 102 euros at Exane BNP Paribas; 88 euros at UBS

Broader market developments are covered in Current market reports.

More news and analyses on Sanofi stock.

Disclaimer...
en | FR0000120578 | SANOFI S.A. | boerse | 70485239 | bgmi